Clinical and laboratory outcomes during the treatment of rheumatoid arthritis with methotrexate.
Ten clinical and three laboratory outcomes were evaluated in 86 patients completing a double-blind placebo-controlled trial of methotrexate in rheumatoid arthritis. The improvement in all measured outcomes was statistically significantly better in patients receiving methotrexate than in patients receiving placebo. The correlations of the changes in outcome measures were calculated to determine if improvement in one parameter was associated with improvement in other clinical parameters. Associations between different clinical outcomes were often statistically significant. Associations between laboratory outcomes were also often statistically significant. However, the association between clinical outcomes and laboratory outcomes was generally poor.
Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City.
G W
GW
Cannon
J C
JC
Reading
J R
JR
Ward
L J
LJ
Blonquist
L B
LB
Collette
D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D002097:C-Reactive Protein / Q000378:metabolism; D004311:Double-Blind Method; D004487:Edema / Q000473:pathology; D005455:Fluorescent Antibody Technique; D006801:Humans; D007841:Latex Fixation Tests; D008727:Methotrexate / Q000627:therapeutic use*; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012217:Rheumatoid Factor / Q000378:metabolism
D002097:C-Reactive Protein; D012217:Rheumatoid Factor; D008727:Methotrexate